Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Valencia, Spain; Interuniversity Research Institute for Molecular Recognition and Technological Development, Polytechnic University of Valencia-University of Valencia, Valencia, Spain; Simulation Department, Empresarios Agrupados Internacional S.A., Madrid, Spain.
Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Valencia, Spain; Interuniversity Research Institute for Molecular Recognition and Technological Development, Polytechnic University of Valencia-University of Valencia, Valencia, Spain.
Comput Methods Programs Biomed. 2024 Jan;243:107929. doi: 10.1016/j.cmpb.2023.107929. Epub 2023 Nov 18.
In silico methods have become the key for efficiently testing and qualifying drug properties. Due to the complexity of the LADME processes and drug characteristics associated to oral drug absorption, there is a growing demand in the development of Physiologically-based Pharmacokinetic (PBPK) software with greater flexibility. Thus, the aims of this work are (i) to develop a mechanistic-based modeling framework of dissolution, transit and absorption (Phys-DAT) processes in the PhysPK platform and (ii) to assess the predictive power of the acausal MOOM methodology embedded in Phys-DAT versus reference ODE-based PBPK software.
A PBPK model was developed including unreleased, undissolved and dissolved thermodynamic states of the drug. The gastrointestinal tract (GI) was represented by nine compartments and first-order transit kinetics was assumed for the drug fractions. Dissolution processes were described using solubility-independent or solubility-dependent mechanisms and pH effects. Linear transit and linear absorption mechanisms including gradual decrease absorption rate were considered to represent the passive diffusion process. Internal validation of the Phys-DAT model was performed through simulation-based analysis, considering different theoretical scenarios. External validation was carried out using in silico and in vivo data of GI segments and plasma concentrations. Both BCS I and II class drugs were included.
The model predicts plasma-concentration profiles of each compartment for undissolved, dissolved, and absorbed fractions using PhysPK® v.2.4.1. Internal and external validations demonstrate that the model aligned with the theoretical assumptions and accurately predicted C, T, and AUC for both BCS I and II drugs. Average Fold Error (AFE), Absolute Average Fold Error (AAFE), and Percent Prediction Error (PPE) calculations indicate good predictive performance, with predicted/observed ratios falling within the acceptable range.
Phys-DAT represents a mechanistic model for predicting oral absorption, including the dissolution, pH effect, transit, and absorption processes. PhysPK has shown to be a tool with strong prediction accuracy, similar to the obtained by ODE-based PBPK reference software, and the results obtained with the Phys-DAT model for oral administered drugs showed predictive reliability in healthy volunteers, setting the basis to determine the interchangeability of the acausal MOOM methodology with other modeling approaches.
在药物性质的高效测试和评估中,计算方法已成为关键。由于 LADME 过程和与口服药物吸收相关的药物特性复杂,因此对具有更大灵活性的基于生理的药代动力学(PBPK)软件的开发需求日益增长。因此,本研究的目的是(i)在 PhysPK 平台中开发一种用于溶解、转运和吸收(Phys-DAT)过程的基于机制的建模框架,以及(ii)评估 Phys-DAT 中嵌入的因果无关 MOOM 方法相对于参考基于 ODE 的 PBPK 软件的预测能力。
开发了一个 PBPK 模型,其中包括药物的未释放、未溶解和溶解热力学状态。胃肠道(GI)用九个隔室表示,并假设药物分数的一级转运动力学。溶解过程使用不依赖于溶解度或依赖于溶解度的机制以及 pH 效应进行描述。线性转运和线性吸收机制包括逐渐降低吸收速率,用于代表被动扩散过程。Phys-DAT 模型的内部验证通过基于模拟的分析进行,考虑了不同的理论方案。外部验证使用 GI 段和血浆浓度的体内和体内数据进行。包括 BCS I 和 II 类药物。
该模型使用 PhysPK® v.2.4.1 预测未溶解、溶解和吸收分数的每个隔室的血浆浓度曲线。内部和外部验证表明,该模型与理论假设一致,准确预测了 BCS I 和 II 类药物的 C、T 和 AUC。平均折叠误差(AFE)、绝对平均折叠误差(AAFE)和百分比预测误差(PPE)计算表明,预测性能良好,预测/观察比值落在可接受范围内。
Phys-DAT 代表了一种用于预测口服吸收的机制模型,包括溶解、pH 效应、转运和吸收过程。PhysPK 已被证明是一种具有强大预测准确性的工具,与基于 ODE 的 PBPK 参考软件的准确性相当,Phys-DAT 模型用于口服给药药物的结果在健康志愿者中显示出可靠的预测能力,为确定因果无关 MOOM 方法与其他建模方法的可互换性奠定了基础。